Ibritumomab tiuxetan

{
  "id": "MLC-T-ONC-004109",
  "term": "Ibritumomab tiuxetan",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults with certain types of B-cell non-Hodgkin lymphoma. It is also being studied in the treatment of other types of cancer. Ibritumomab tiuxetan contains a monoclonal antibody that binds to a protein called CD20, which is found on B cells and some types of lymphoma cells. It also contains the compound tiuxetan, which allows certain radioactive substances to be attached to the monoclonal antibody. This may help kill cancer cells. Ibritumomab tiuxetan is a type of monoclonal antibody and a type of immunoconjugate. Also called Zevalin.",
    "An immunoconjugate of the monoclonal antibody ibritumomab conjugated with the linker-chelator tiuxetan, a high affinity, conformationally restricted chelation site for radioisotopes. When bound to indium In 111 or yttrium Y 90, ibritumomab tiuxetan, targeting the CD20 antigen on B cell surfaces, specifically delivers a potentially cytotoxic dose of radiation to B lymphocytes. Ibritumomab is a murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes."
  ],
  "synonyms": [
    "Zevalin"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ibritumomab-tiuxetan/"
}